Chinese lab requests ANVISA approve emergency use of single-dose Covid-19 vaccine

ANVISA said it should issue an opinion within seven working days, if all legal requirements for the request have been met. The agency is conducting a check to ensure that all the information to be assessed by the agency has been submitted.

RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) said on Wednesday, May 19, that it had received a temporary authorization request for the emergency use of a single-dose Covid-19 vaccine developed by Chinese CanSino Biologics laboratory.

In a statement, the Brazilian regulator said it received the application on Tuesday from Belcher Pharmaceuticals, the representative of CanSino Biologics laboratory in Brazil, and that the analysis of the documentation to consider authorizing the vaccine has been initiated.

ANVISA said it should issue an opinion within seven working days, if all legal requirements for the request have been met . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?